chevron_leftBack
As of 5 June 2026, SciSparc Ltd. has a market cap of $5.11M USD, ranking #44411 globally and #586 in Israel.
It ranks #3933 in the Healthcare sector, and #1261 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$5.11MUSD
Enterprise Value
$5.98MUSD
Revenue (TTM)
$1.31MUSD
EBITDA (TTM)
-$7.03MUSD
Net Income (TTM)
-$6.48MUSD
PS Ratio
3.9
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Oz Adler
open_in_new
Employees
2
Founded
2004
Website
scisparc.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 8.3% | 45% | 122% | 15% | -74% | -84% |
News
Loading...
SPRC Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
SPRC
SciSparc Ltd
ISIN: IL0010951403
Shares Out.:
Shares Outstanding:
573.243K1
Shares Float:
573.243K2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
9.03 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About SciSparc Ltd.
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer’s disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufacture SCI-110, palmitoylethanolamide oral tablets and CannAmide in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer’s to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer’s disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: SLGL
|
$231.51M
4K%
|
-
|
|
NASDAQ: MDWD
|
$209.11M
4K%
|
-
|
|
TLV: EPIT
|
$87.12M
2K%
251.95M ILS
|
-
|
|
NASDAQ: PYPD
|
$86.83M
2K%
|
-
|
|
NASDAQ: ENTX
|
$52.68M
932%
|
-
|
|
TLV: REKA
|
$46.34M
807%
134.01M ILS
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
15M%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
11M%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
7M%
|
97.4
|
|
SIX: RO
|
$324.68B
6M%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$289.25B
6M%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$277.35B
5M%
218.9B CHF
|
20.5
|
chevron_leftBack